Personalized peptide vaccination in patients with refractory non-small cell lung cancer
Authors:
Open Access
- 1 February 2012
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 40 (5) , 1492-1500
Abstract
Since the prognosis of non-small cell lung cancer (NSCLC) remains poor, the development of novel therapeutic approaches, including cancer vaccines, is highly desirable. In the current study, we conducted a phase II study of personalized peptide vaccination (PPV), in which a maximum of 4 peptides were selected based on pre-existing humoral immune responses and administered subcutaneously (weekly for 6 consecutive weeks and bi-weekly thereafter) in refractory NSCLC patients. Forty-one refractory NSCLC patients (4 stage IIIb, 22 stage IV and 15 recurrent), who had failed to respond to chemotherapy and/or targeted therapy (median number of regimens, 3; median duration, 10 months), were enrolled. Median overall survival (OS) was 304 days with a one-year survival rate of 42% in the enrolled patients. The main toxicity of PPV was skin reactions at the injection sites, but no serious adverse events were observed. In order to identify potential biomarkers for predicting OS, pre-vaccination and post-vaccination clinical findings and laboratory data were retrospectively assessed and evaluated by multivariate Cox regression analysis. Among the pre-vaccination factors examined, high C-reactive protein (CRP) level was a significant predictor of unfavorable OS [hazard ratio (HR)=10.115, 95% confidence interval (CI)=2.447-41.806, P=0.001]. Among the post-vaccination factors, high CRP level and low frequency of CD3+CD26+ cells were significant predictors of unfavorable OS (HR=23.127, 95% CI=2.919-183.233, P=0.003; HR=0.952, 95% CI=0.917-0.989, P=0.012). Taken together, our results suggest the feasibility of PPV for the treatment of refractory NSCLC. Evaluation of the identified factors before or at an early stage of vaccination could be potentially useful for selecting NSCLC patients who would likely have better prognosis following PPV.Keywords
This publication has 26 references indexed in Scilit:
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality?Nature Reviews Clinical Oncology, 2010
- Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccinesEuropean Journal of Cancer, 2010
- Myeloid-derived suppressor cell heterogeneity and subset definitionCurrent Opinion in Immunology, 2010
- A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancerCancer Immunology, Immunotherapy, 2010
- Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patientsCancer Immunology, Immunotherapy, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Recent Advances in Cancer Vaccines: An OverviewJapanese Journal of Clinical Oncology, 2008
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell functionTrends in Immunology, 2008
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends in Molecular Medicine, 2008
- New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunizationScandinavian Journal of Clinical and Laboratory Investigation, 2004